IS5696A - Mótefni gegn CD23, afleiður þeirra og meðferðarnotkun þeirra - Google Patents

Mótefni gegn CD23, afleiður þeirra og meðferðarnotkun þeirra

Info

Publication number
IS5696A
IS5696A IS5696A IS5696A IS5696A IS 5696 A IS5696 A IS 5696A IS 5696 A IS5696 A IS 5696A IS 5696 A IS5696 A IS 5696A IS 5696 A IS5696 A IS 5696A
Authority
IS
Iceland
Prior art keywords
derivatives
antibodies against
therapeutic use
therapeutic
antibodies
Prior art date
Application number
IS5696A
Other languages
English (en)
Inventor
Marcel Paul Bonnefoy Jean-Yves
James Crowe Scott
Henry Ellis Jonathan
Timothy Rapson Nicholas
Shearin Jean
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS5696A publication Critical patent/IS5696A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IS5696A 1998-05-09 2000-10-31 Mótefni gegn CD23, afleiður þeirra og meðferðarnotkun þeirra IS5696A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9809839.5A GB9809839D0 (en) 1998-05-09 1998-05-09 Antibody
PCT/GB1999/001434 WO1999058679A1 (en) 1998-05-09 1999-05-07 Antibodies to cd23, derivatives thereof, and their therapeutic uses

Publications (1)

Publication Number Publication Date
IS5696A true IS5696A (is) 2000-10-31

Family

ID=10831668

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5696A IS5696A (is) 1998-05-09 2000-10-31 Mótefni gegn CD23, afleiður þeirra og meðferðarnotkun þeirra

Country Status (25)

Country Link
US (1) US7008623B1 (is)
EP (1) EP1076701A1 (is)
JP (1) JP2002514421A (is)
KR (1) KR20010043470A (is)
CN (1) CN1308676A (is)
AP (1) AP1547A (is)
AU (1) AU763491B2 (is)
BR (1) BR9910327A (is)
CA (1) CA2328606A1 (is)
EA (1) EA200001041A1 (is)
EE (1) EE200000658A (is)
GB (1) GB9809839D0 (is)
HR (1) HRP20000762A2 (is)
HU (1) HUP0102005A3 (is)
ID (1) ID28088A (is)
IL (1) IL139384A0 (is)
IS (1) IS5696A (is)
NO (1) NO20005632L (is)
NZ (1) NZ507879A (is)
PL (1) PL344019A1 (is)
SK (1) SK16762000A3 (is)
TR (1) TR200003281T2 (is)
WO (1) WO1999058679A1 (is)
YU (1) YU69000A (is)
ZA (1) ZA200006312B (is)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
NZ525793A (en) 2000-10-13 2008-04-30 Biogen Idec Inc Humanized anti-LT-beta-R antibodies
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
CN1678625A (zh) * 2002-07-01 2005-10-05 比奥根艾迪克Ma公司 人源化抗淋巴毒素β受体的抗体
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
CA2434668A1 (en) 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
WO2005060368A2 (en) * 2003-12-10 2005-07-07 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
BRPI0509201A (pt) 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
US20060246075A1 (en) * 2004-09-29 2006-11-02 Marc Mercken Anti-amyloid antibodies, compositions, methods and uses
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
SI3045182T1 (en) 2005-11-14 2018-08-31 Teva Pharmaceuticals International Gmbh An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
EP1804172B1 (en) * 2005-12-20 2021-08-11 Roche Diagnostics GmbH PCR elbow determination using curvature analysis of a double sigmoid
US7680868B2 (en) * 2005-12-20 2010-03-16 Roche Molecular Systems, Inc. PCR elbow determination by use of a double sigmoid function curve fit with the Levenburg-Marquardt algorithm and normalization
WO2009043051A2 (en) * 2007-09-27 2009-04-02 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
TW200944231A (en) 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs
KR101304150B1 (ko) 2008-03-04 2013-09-05 라브리스 바이올로직스 인코포레이티드 만성 통증의 치료 방법
PE20091964A1 (es) 2008-05-06 2010-01-09 Glaxo Group Ltd Encapsulacion de agentes biologicamente activos
US20110305693A1 (en) 2009-02-24 2011-12-15 Glaxo Group Limited Anitigen-binding constructs
CA2753287A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
EP2401296A1 (en) 2009-02-24 2012-01-04 Glaxo Group Limited Multivalent and/or multispecific rankl-binding constructs
WO2010115786A1 (en) 2009-04-01 2010-10-14 Glaxo Group Limited Anti-il-23 immunoglobulins
EP2421611A1 (en) 2009-04-24 2012-02-29 Glaxo Group Limited Fgfr1c antibody combinations
BR112012004464B8 (pt) 2009-08-28 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica
FR2957598B1 (fr) * 2010-03-17 2015-12-04 Lfb Biotechnologies Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes
MX351887B (es) 2010-11-23 2017-11-01 Glaxo Group Ltd Proteinas de union a antigeno para oncostatina m (osm).
MX2013005847A (es) 2010-11-24 2013-12-12 Glaxo Group Ltd Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf.
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
EP2714737A1 (en) 2011-05-27 2014-04-09 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
EP2888279A1 (en) 2012-08-22 2015-07-01 Glaxo Group Limited Anti lrp6 antibodies
US10176293B2 (en) 2012-10-02 2019-01-08 Roche Molecular Systems, Inc. Universal method to determine real-time PCR cycle threshold values
RS60538B1 (sr) 2013-03-15 2020-08-31 Glaxosmithkline Ip Dev Ltd Anti-lag-3 vezujući proteini
US9777057B2 (en) * 2013-07-10 2017-10-03 Onconox Aps Antibodies to β2-glycoprotein I and therapeutic uses thereof
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX378344B (es) 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
RU2760582C2 (ru) 2015-09-02 2021-11-29 Иммутеп С.А.С. Анти-LAG-3 антитела
US10479827B2 (en) 2016-05-31 2019-11-19 Sysmex Corporation Monoclonal antibody reacting with glycopeptide, and use thereof
JP6935184B2 (ja) * 2016-05-31 2021-09-15 シスメックス株式会社 糖ペプチドと反応するモノクローナル抗体およびその用途
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
SMT202600087T1 (it) 2016-09-23 2026-03-09 Teva Pharmaceuticals Int Gmbh Trattamento dell’emicrania refrattaria
WO2019143948A1 (en) 2018-01-18 2019-07-25 Fred Hutchinson Cancer Research Center Altering inflammatory states of immune cells in vivo by modulating cellular activation states
KR20210099614A (ko) 2018-12-04 2021-08-12 노파르티스 아게 Cd3에 대한 결합 분자 및 이의 용도
AU2020279224B2 (en) 2019-05-21 2024-12-05 Novartis Ag Trispecific binding molecules against BCMA and uses thereof
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
CA3143211A1 (en) 2019-06-26 2020-12-30 Glaxosmithkline Intellectual Property Development Limited Il1rap binding proteins
CN112552403A (zh) * 2020-12-25 2021-03-26 南京英瀚斯生物科技有限公司 一种人源抗人CD23抗体的Fab片段、药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
NZ243706A (en) 1991-07-25 1994-08-26 Idec Pharma Corp Recombinant monkey antibodies, pharmaceutical compositions
HU223006B1 (hu) * 1994-10-25 2004-03-01 Glaxo Group Ltd. CD23-hoz kötődő vegyületek
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies

Also Published As

Publication number Publication date
BR9910327A (pt) 2001-01-30
WO1999058679A1 (en) 1999-11-18
CN1308676A (zh) 2001-08-15
CA2328606A1 (en) 1999-11-18
JP2002514421A (ja) 2002-05-21
PL344019A1 (en) 2001-09-24
HRP20000762A2 (en) 2001-06-30
HUP0102005A3 (en) 2003-10-28
AP2000001983A0 (en) 2000-12-31
EE200000658A (et) 2002-04-15
EA200001041A1 (ru) 2001-06-25
AU763491B2 (en) 2003-07-24
NZ507879A (en) 2004-02-27
IL139384A0 (en) 2001-11-25
GB9809839D0 (en) 1998-07-08
US7008623B1 (en) 2006-03-07
EP1076701A1 (en) 2001-02-21
NO20005632D0 (no) 2000-11-08
ID28088A (id) 2001-05-03
HUP0102005A2 (hu) 2001-10-28
KR20010043470A (ko) 2001-05-25
YU69000A (sh) 2003-08-29
SK16762000A3 (sk) 2001-07-10
TR200003281T2 (tr) 2001-03-21
NO20005632L (no) 2001-01-08
AU3836799A (en) 1999-11-29
AP1547A (en) 2006-01-13
ZA200006312B (en) 2003-02-26

Similar Documents

Publication Publication Date Title
EE200000658A (et) CD23 antikehad, nende derivaadid ja nende terapeutiline kasutamine
NO20021449D0 (no) Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og anvendelse derav
NO20021379D0 (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
NO20012567D0 (no) Azepinoindolderivater, fremstilling og anvendelse derav
IS6385A (is) Ný notkun og nýjar N-asabísýkló-amíð afleiður
NO20014560D0 (no) Quinasoliner og terapautisk anvendelse derav
DK0869126T3 (da) Dithiolanderivater, deres fremstilling og deres terapeutiske virkning
DK1454907T3 (da) Quninazolin og pyridopyrmidin-derivativer
IS2277B (is) Meðferðarlegar bíarýl afleiður
NO980720D0 (no) Pyridazin-3-on-derivater, deres anvendelse og mellomprodukter for deres fremstilling
DK0832104T3 (da) Dolastatinderivater, deres fremstilling og anvendelse
DK1019358T3 (da) 3,3-diarylpropylaminer, deres anvendelse og fremstilling
DK1073672T3 (da) Antipicornavirale forbindelser, deres fremstilling og anvendelse
TR199800117A3 (tr) Isaksazol- ve krotonasitamid türevleri ve bunlarin kullanimi.
DK1106607T3 (da) Uracilforbindelser og anvendelse deraf
NO20013237L (no) 3,3-biarylpiperidin og 2,2-biarylmorfolinderivater
DK1417189T3 (da) Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf
NO986174D0 (no) Triazinderivater og anvendelse derav
DK1025100T3 (da) 3-substituerede tetrahydropyridopyrimidinonderivater, fremstilling og anvendelsen heraf
DK1140952T3 (da) Phosphororganiske forbindelser og anvendelse heraf
PT1178981E (pt) 3-piridil-4-arilpirrois substituidos e metodos terapeuticos e profilacticos
NO308213B1 (no) Substituerte indanylidinacetylguanidiner, deres anvendelse og medikamenter inneholdende forbindelsene
NO20000066D0 (no) 6-pyrrolidin-2-ylpyrindin-derivater, deres fremstilling og deres farmasoeytiske anvendelse
NO20003268L (no) Hyperhydrert kitikolin, fremgangsmÕte og anvendelse
NO20006479D0 (no) Tienopyridinforbindelser, deres fremstilling og anvendelse